Posters and Publications

This page is intended to provide scientific information to research and healthcare professionals. Evofem Biosciences’ first commercial product was recently approved by the Food and Drug Administration. The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. EVO100 has not been approved by the Food and Drug Administration or any other regulatory agency.

Author(s)

Publication

Title

Date

Thomas, et al. 

Contraception X  

A Novel Vaginal pH Regulator: Results From The Phase 3 AMPOWER Contraception Clinical Trial

July 2020 

Chappell, et al. 

Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecology (ACOG) 

Perfect-Use Pregnancy Rates with Vaginal pH Regulator: Efficacy Results from AMPOWER

April 2020 

Thomas, et al. 

Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecology (ACOG) 

Sexual Satisfaction With Vaginal pH Regulator: Results From The AMPOWER Clinical Trial

April 2020 

Maximos, et al. 

Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecology (ACOG) 

Genitourinary Side Effects With Vaginal pH Regulator: Results From AMPOWER

April 2020 

Cason, et al. 

Nurse Practitioners in Women’s Health (NPWH) Healthcare Conference 

Efficacy and Safety of a Vaginal pH Regulator: Results from the Phase 3, AMPOWER Clinical Trial

Oct. 2019 

Thomas, et al.

American Society of Reproductive Medicine (ASRM)

Women’s Satisfaction with the Vaginal pH Regulator (VPRTM): Results From the Phase 3 AMPOWER Trial

Oct. 2019

Culwell K, et al.

Fertility and Sterility

A randomized, placebo-controlled pilot study to determine the effect and duration of Acidfrom gel (Amphora) on vaginal pH

Oct. 2017

Friend D

2nd International Conference on Reproductive Health

Amphora vaginal gel: An on-demand contraceptive with anti-STI (MPT) potential

Dec. 2016

Thomas M, et al.

Contraception Journal

Gynecologic infections and colposcopy fidings from a phase 3 efficacy and safety study of a contracpetive vaginal gel compared with nonoxynol-9

Oct. 2016

Barnhard K, et al.

Obstetrics & Gynecology

Contraceptive efficacy, safety, and acceptability of Amphora (an acid-buffering vaginal gel) and Conceptrol

May 2016

Bayer L, et al. 

Contraception Journal

ACIDFORM: a review of the evidence

July 2014

Evofem assumes no responsibility for the accuracy of any information or data contained on any third party website.  Evofem has not independently verified the accuracy of such information or data, and there can be no assurance as to the accuracy of any such information or data.  Links to this information and data are provided for informational purposes only.